CDCA7L在人脑胶质瘤组织中的表达及意义

目的 探讨细胞分裂周期相关7样蛋白（CDCA7L）在胶质瘤组织中的表达及其与病人预后的关系。方法 免疫组织化学染色法检测2012年1月至2013年5月手术切除的112例胶质瘤组织和2018年1~12月颅脑损伤内减压术中切除的45例正常脑组织中CDCA7L的表达水平，根据染色情况将胶质瘤病人分为高表达组和低表达组。胶质瘤病人随访截止2019年6月，记录总生存期（OS）和无进展生存期（PFS）。结果 胶质瘤组织CDCA7L高表达率（66.96%，75/112）明显高于正常脑组织（17.78%，8/45；P<0.05）。高级别胶质瘤组织CDCA7L高表达率（79.41%，54/68）明显高于低级别胶质瘤（47.73%，21/44；P<0.05）。多因素Cox比例风险回归模型分析结果显示，CDCA7L高表达是胶质瘤病人OS和PFS较短的独立影响因素（P<0.05）。生存曲线分析显示，高表达组中位OS（21个月，四分位区间16~41个月）和中位PFS（18个月，四分位区间13~38个月）均明显低于低表达组分别为60个月（48~65个月）和45个月（41~52个月）；P<0.05]。结论 胶质瘤组织CDCA7L呈高表达，而且与胶质瘤不良生存预后和肿瘤进展有关。

Expression of CDCA7L in human glioma tissues and its clinical significance

Objective To investigate the expression of cell division cycle associated 7-like protein (CDCA7L) in human glioma tissues and its relationship with patients’ prognosis. Methods The expression level of CDCA7L in human glioma tissues obtained from 112 patients with glioma who underwent microsurgery from January 2012 to May 2013 and in normal brain tissues obtained from 45 patients with traumatic brain injury who underwent decompression from January to December 2018 were detected by immunohistochemical staining. According to the staining, the glioma patients were divided into high expression group and low expression group. The follow-up of glioma patients ended in June 2019, and the overall survival (OS) and progression-free survival (PFS) were recorded. Results The high expression rate of CDCA7L in glioma tissues (66.96%, 75/112) was significantly higher than that (17.78%, 8/45) in normal brain tissues (P<0.05). The high expression rate of CDCA7L in high-grade glioma tissues (79.41%, 54/68) was significantly higher than that (47.73%, 21/44) in low-grade glioma tissues (P<0.05).The multivariate Cox proportional hazard regression model analysis showed that the high expression of CDCA7L was an independent risk factor for shorter OS and PFS in glioma patients (P<0.05). The OS and PFS in the low-expression group were significantly higher than those in the high-expression group (P<0.05). Conclusions The CDCA7L is highly expressed in glioma tissue. The high expression of CDCA7L is related to the poor survival prognosis and tumor progression of glioma patients.